$EW

Zovighian Bernard J sold $245K of EW (indirect holdings)

Zovighian Bernard J (CEO) sold 2,921 indirectly-held shares of Edwards Lifesciences Corp (EW) at $83.93 ($0.25M total) on 2026-07-27.

Original reporting
SEC EDGAR · Zovighian Bernard J
Published Jul 27, 2026, 10:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 11:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EW
Neutral
medium confidence
Mentioned
$EW
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale of 2,921 shares at $83.9342 on 2026-07-27, totaling $245,134.12, with holdings after sale of 8,916 shares and no pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not change the company’s fundamentals.

03

What to watch

The filing notes indirect holdings and post-transaction share count, but does not disclose the broader trading history, tax events, or whether other insiders executed offsetting buys.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed today, 2026-07-27 (after-hours filing timestamp).

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Edwards Lifesciences (EW).

Company-level read

Ticker impact

$EWNeutralMedium confidence
Context

Edwards Lifesciences CEO Zovighian sold 2,921 shares in an open-market transaction for about $245K, disclosed via Form 4 today.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no new operational, financial, or regulatory information. Insider sales can be interpreted both ways, and the disclosed value is modest relative to typical market capitalization.

Market effects

No direct sector read-through; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs, and the absence of a 10b5-1 plan does not necessarily imply negative expectations without additional context.

Key entities

  • Edwards Lifesciences Corp

    US-listed medical device company subject of the Form 4 insider sale disclosure.

  • Zovighian Bernard J

    CEO and officer/director who sold shares via an open-market transaction.

Related articles

$EWMedAI 8/10

FTC Reaches $12 Million Settlement Over Alleged HSR Act Violations

The FTC proposed a settlement with Edwards Lifesciences and Genesis MedTech over alleged Hart-Scott-Rodino filing violations tied to Edwards’ July 2024 $115 million acquisition of JC Medical. The FTC says a $25 million Genesis non-voting share investment was additional deal consideration, making the combined value reportable. Edwards would pay $10 million and Genesis $2 million.

$EWMedAI 8/10

Edwards Reports Q2 Sales Climb 14% to $1.74B

Edwards Lifesciences (NYSE: EW) reported Q2 revenue of $1.74B, up 14% year over year, and adjusted EPS of 78 cents, above expectations. Full-year sales guidance was raised to 10%-11%. TAVR sales grew 11% to $1.26B. CMS draft Medicare coverage could expand TAVR access, with a final decision expected in September.

$EWMedAI 8/10

Edwards Lifesciences Wins FDA Clearance for Ecliptis Left Atrial Appendage Clip

Edwards Lifesciences said the FDA cleared its Ecliptis left atrial appendage exclusion system for use during cardiac surgery to help prevent clot formation in atrial fibrillation. The company plans a preliminary launch later this year and expects to leverage its surgical valve footprint. The article also notes FDA Breakthrough designation for Aidoc’s AI and OTC Dexcom Stelo clearance for children.

$EWMed

Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary

Edwards Lifesciences (EW) reported Q2 2026 sales up 12.5%, driven by structural heart growth across TAVR and TMTT. Management raised full-year 2026 sales guidance to 10% to 11% and expects TMTT revenue to reach $2B by 2030. Key catalysts include U.S. TAVR NCD in September and PROGRESS trial results later in 2026.